UnknownNot Applicable

Clinical Long Term Evaluation of Glutamine Supplement in MELAS Syndrome

Spain9 participantsStarted 2021-07-01

Plain-language summary

The purpose of this study is to assesses the clinical efficacy of oral supplementation with glutamine over 3 years.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * MELAS syndrome Clinically and genetically confirmed. * Patients have already participated in GLN-9-MIT study Exclusion Criteria: * subjects harboring a MELAS-related pathogenic mtDNA mutation no fulfilling the complete diagnostic criteria for the MELAS phenotype

What they're measuring

Clinical efficacy; JMDRS

Timeframe: 36 months

Clinical efficacy; MMSE

Timeframe: 36 months

Trial details

NCT IDNCT05255328

SponsorHospital Universitario 12 de Octubre

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-07-15

View on ClinicalTrials.gov More MELAS Syndrome trials